Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis

Modern Rheumatology

Volumn 17, Issue 6, 2007, Pages 481-485

  Eguchi, Katsumi ^a   Saito, Kazuyoshi ^b   Kondo, Masakazu ^c   Hidaka, Toshihiko ^d   Ueki, Yukitaka ^e   Tanaka, Yoshiya ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

^d Zenjinkai Shimin no Mori Hospital   (Japan)

^e SASEBO CHUO HOSPITAL   (Japan)

Author keywords

Extracorporeal circulation; Leukocytapheresis; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADSORPTION; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTAPHERESIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; EXTRACORPOREAL CIRCULATION; FEMALE; FILTER; HUMAN; INTERMETHOD COMPARISON; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FILTRATION; HUMANS; JOINTS; LEUKAPHERESIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37449016409     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0630-7     Document Type: Article

References (27)

1. The guideline committee of the Japanese Society for Dialysis Therapy 2002 Guidelines for the management of rheumatoid arthritis Arthritis Rheum 46 328-46 10.1002/art.10148
2. FC Breedveld P Emery E Keystone K Patel DE Furst JR Kalden 2004 Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63 149-55 14722203 10.1136/ard.2003.013961 1:CAS:528:DC%2BD2cXhsVGnsLY%3D
3. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 1594-602 11096166 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D
4. T Bongartz AJ Sutton MJ Sweeting I Buchan EL Matteson V Montori 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 2275-85 16705109 10.1001/jama.295.19.2275 1:CAS:528:DC%2BD28Xksl2ktrk%3D
5. J Tenenbaum MB Urowitz EC Keystone IL Dwosh JE Curtis 1979 Leucapheresis in severe rheumatoid arthritis. Ann Rheum Dis 38 40-4 434945 1:STN:280:CSaC28vmtFY%3D
6. DJ Wallace D Goldfinger R Gatti C Lowe P Fan R Bluestone JR Klinenberg 1979 Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. Arthritis Rheum 22 703-10 454499 10.1002/ art.1780220703 1:STN:280:CSaB3cbjtF0%3D
7. J Karsh DG Wright JH Klippel JL Decker AB Deisseroth MW Flye 1979 Lymphocyte depletion by continuous flow cell centrifugation in rheumatoid arthritis: Clinical effects. Arthritis Rheum 22 1055-9 486218 10.1002/art.1780221002 1:STN:280:Bi%2BD38%2FjslQ%3D
8. J Karsh JH Klippel PH Plotz JL Decker DG Wright MW Flye 1981 Lymphapheresis in rheumatoid arthritis. A randomized trial. Arthritis Rheum 24 867-73 7020704 10.1002/art.1780240701 1:STN:280:Bi6B2MrovFM%3D
9. D Wallace D Goldfinger C Lowe S Nichols J Weiner M Brachman 1982 A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. N Engl J Med 306 1406-10 7043264 1:STN:280:Bi2C1MrjvFU%3D
10. SM Wahl RL Wilder IM Katona LM Wahl JB Allen I Scher 1983 Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal of anergy. Arthritis Rheum 26 1076-84 6615562 10.1002/ art.1780260904 1:STN:280:BiyA3cfoslA%3D
11. W Verdickt J Dequeker JL Ceuppens E Stevens K Gautama C Vermylen 1983 Effect of lymphoplasmapheresis on clinical indices and T cell subsets in rheumatoid arthritis. A double-blind controlled study. Arthritis Rheum 26 1419-26 6360178 10.1002/art.1780261202 1:STN:280:BiuD1c%2Fgt1A%3D
12. T Hidaka K Suzuki Y Matsuki M Takamizawa-Matsumoto K Kataharada T Ishizuka 1999 Filtration leukocytapheresis therapy in rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42 431-7 10088764 10.1002/ 1529-0131(199904)42:3<431::AID-ANR6>3.0.CO;2-2 1:STN:280:DyaK1M7os1Khtw%3D%3D
13. Y Ueki S Yamasaki Y Kanamoto T Kawazu M Yano K Matsumoto 2000 Evaluation of filtration leucocytapheresis for use in the treatment of patient with rheumatoid arthritis. Rheumatology 39 165-71 10725066 10.1093/ rheumatology/39.2.165 1:STN:280:DC%2BD3c7ptVSnsA%3D%3D
14. K Kempe H Tsuda K Yang K Yamaji Y Kanai H Hashimoto 2004 Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate. Ther Apher Dial 8 197-205 15154871 10.1111/j.1526-0968.2004.00132.x 1:CAS:528:DC%2BD2cXmtlSlurw%3D
15. Y Izumi M Tominaga N Iwanaga M Huang F Tanaka K Aratake 2006 Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis. Mod Rheumatol 16 20-3 16622719 10.1007/ s10165-005-0448-0
16. Ueki Y, Sagawa A, Tanimura K, Yamada A, Yamamoto K, Tsuda H, et al. A multicenter study of leukocytapheresis in rheumatoid arthritis. Clin Exp Rheumatol; in press
17. ML Prevoo MA van 't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44-8 7818570 10.1002/art.1780380107 1:STN:280:ByqC3MfjvFI%3D
18. DAS-Score.nl [homepage on the Internet]. Netherlands: The department of rheumatology, University Medical Centre Nijmegen. Available from: http://www.das-score.nl/
19. T Nishimura S Oka N Yamawaki 1994 Technical aspects of leucocyte depletion CF Hogman Leucocyte depletion of blood components VU University Press Amsterdam 51-8
20. Y Ueki H Nakamura Y Kanamoto M Miyazaki M Yano K Matsumoto 2001 Comparison of lymphocyte depletion and clinical effectiveness on filtration leukocytapheresis in patients with rheumatoid arthritis. Ther Apher 5 455-61 11800080 10.1046/j.1526-0968.2001.00375.x 1:STN:280:DC%2BD38%2FnsVarsw%3D%3D
21. T Hidaka K Suzuki Y Matsuki M Takamizawa-Matsumoto M Okada T Ishizuka 1999 Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher 3 178-85 10341394 10.1046/ j.1526-0968.1999.00136.x 1:STN:280:DyaK1M3nt12nsg%3D%3D
22. RW Kinne R Brauer B Stuhlmuller E Palombo-Kinne GR Burmester 2000 Macrophages in rheumatoid arthritis. Arthritis Res 2 189-202 11094428 10.1186/ar86 1:CAS:528:DC%2BD3cXlslyis7g%3D
23. G Hahn B Stuhlmuller N Hain JR Kalden K Pfizenmaier GR Burmester 1993 Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest 91 862-70 8450066 1:CAS:528:DyaK3sXisVSqsr8%3D
24. F Wang NS Wang CG Yan JH Li LQ Tang 2007 The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol 26 768-71 17279322 10.1007/s10067-007-0550-0
25. K Fukunaga Y Fukuda Y Yokoyama K Ohnishi T Kusaka T Kosaka 2006 Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 41 524-32 16868799 10.1007/s00535-006-1789-y
26. Y Yagi A Andoh O Inatomi S Bamba T Tsujikawa Y Fujiyama 2006 Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 41 540-6 16868801 10.1007/s00535-006-1797-y
27. S Onuma K Yamaji K Kempe M Ogasawara T Ogawa K Yang 2006 Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. Ther Apher Dial 10 404-11 17096694 10.1111/j.1744-9987.2006.00403.x